2-(4-propylcyclohexyl)acetic acid | 74603-24-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(4-propylcyclohexyl)acetic acid
• 英文别名: trans-4-n-Propylcyclohexyl-essigsaeure；trans-4-n-propylcyclohexylacetic acid；(4-Propylcyclohexyl)acetic acid
• CAS: 74603-24-0
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.279
• InChiKey: UIUUWKDQRHXTBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-propylcyclohexyl)acetic acid 在 硫酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 7.0h， 生成
  参考文献：
  名称：

  液晶性化合物、液晶組成物および液晶表示素子

  摘要：

  【问题】本发明提供一种液晶性化合物，该化合物至少满足以下物性之一：对热和光的高稳定性、高透明点（或高上限温度）、液晶相的低下限温度、小粘度、适当的光学異方性、小的或负的大电介质異方性、适当的弹性常数、与其他液晶性化合物良好的相容性。本发明还提供一种含有该化合物的液晶组成物和一种包含该组成物的液晶显示器件。 【解决手段】本发明的解决手段是化合物等，如式（1）所示。其中，R1和R2是氢、烷基等；环A1、A2、A3和A4是1,4-环己烯、1,4-苯基等；Z1、Z2、Z3和Z4是单键、烷基等；a、b、c和d是0、1或2；连接基-CH(CH3)-CH(CH3)-的立体构型是treo。 【选图】无

  公开号：

  JP2020158394A
• 作为产物：
  描述：

  trans-4-n-propylcyclohexylmethyl bromide 在 苯基溴化镁 作用下， 生成 2-(4-propylcyclohexyl)acetic acid
  参考文献：
  名称：

  Liquid crystal compounds

  摘要：

  具有以下化学式的液晶化合物：##STR1## 其中 X 是 --CH.sub.2.CH.sub.2 -- 或 CH.sub.2 O，Y 是 ##STR2##，R 是具有多达15个碳原子的直链或支链（可能手性的）烷基基团。

  公开号：

  US04261651A1

文献信息

• [EN] FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS<br/>[FR] FURO[3,2-B]PYRROL-3-ONES EN TANT QU'INHIBITEURS DE CATHÉPSINE S
  申请人：AMURA THERAPEUTICS LTD

  公开号：WO2009112826A1

  公开（公告）日：2009-09-17

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R3 and R4 is H, and the other is selected from C1-6-alkyl, C1-6-haloalkyl, C1-6- alkoxy, and C6-12-aralkyl; or R3 and R4 are each independently selected from C1-6-aIkyl and halo; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.

  本发明的第一个方面涉及式（I）的化合物，或其药学上可接受的盐，水合物，复合物或前药，其中：R3和R4中的一个为H，另一个选自C1-6烷基，C1-6卤代烷基，C1-6烷氧基和C6-12芳基烷基; 或R3和R4各自独立地选自C1-6烷基和卤素; R9是取代的5或6成员芳基或杂芳基或6,5-或6,6-融合的双芳基或双杂芳基。式（I）的化合物表现出对人类卡特普辛S的惊人高效性，对其他哺乳动物卡特普辛具有优异的选择性，并可用于治疗风湿性关节炎，多发性硬化症，重症肌无力，移植排斥反应，糖尿病，Sjogrens综合症，Grave病，系统性红斑狼疮，骨关节炎，银屑病，特发性血小板减少性紫癜，过敏性鼻炎，哮喘，动脉粥样硬化，肥胖症，慢性阻塞性肺疾病和慢性疼痛等疾病的治疗。
• FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS
  申请人：AMURA THERAPEUTICS LIMITED

  公开号：US20130150345A1

  公开（公告）日：2013-06-13

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R 3 and R 4 is H, and the other is selected from C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkoxy, and C 6-12 -aralkyl; or R 3 and R 4 are each independently selected from C 1-6 -alkyl and halo; R 9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.

  本发明的第一个方面涉及公式(I)的化合物，或其药学上可接受的盐、水合物、复合物或前药，其中：R3和R4中的一个为H，另一个选自C1-6-烷基、C1-6-卤代烷基、C1-6-烷氧基和C6-12-芳基烷基; 或R3和R4各自独立地选自C1-6-烷基和卤代基; R9是取代的5或6成员芳基或杂芳基或6,5-或6,6-螺合的双芳基或双杂芳基。公式(I)的化合物表现出对人类卡特普汀S的惊人高效性，对其他哺乳动物卡特普汀具有优异的选择性，并可用于治疗风湿性关节炎、多发性硬化症、重症肌无力、移植排斥、糖尿病、Sjogrens综合症、Grave's病、全身性红斑狼疮、骨关节炎、牛皮癣、特发性血小板减少性紫癜、过敏性鼻炎、哮喘、动脉粥样硬化、肥胖症、慢性阻塞性肺疾病和慢性疼痛等疾病的治疗。
• FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS
  申请人：Amura Therapeutics Limited

  公开号：US20160015685A1

  公开（公告）日：2016-01-21

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R 3 and R 4 is H, and the other is selected from C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkoxy, and C 6-12 -aralkyl; or R 3 and R 4 are each independently selected from C 1-6 -alkyl and halo; R 9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.

  本发明的第一个方面涉及公式（I）的化合物，或其药学上可接受的盐、水合物、复合物或前药，其中：R3和R4中的一个是H，另一个被选自C1-6-烷基，C1-6-卤代烷基，C1-6-烷氧基和C6-12-芳基烷基；或R3和R4各自独立地选自C1-6-烷基和卤；R9是取代的5或6元杂环芳基或杂芳基基团或6,5-或6,6-螺合的双芳基或双杂芳基基团。公式（I）的化合物表现出对人类卡特普辛S意外的高效性，对其他哺乳动物卡特普辛具有良好的选择性，并可用于治疗风湿性关节炎、多发性硬化症、重症肌无力、移植排斥反应、糖尿病、Sjogrens综合症、Grave病、系统性红斑狼疮、骨关节炎、牛皮癣、特发性血小板减少性紫癜、过敏性鼻炎、哮喘、动脉粥样硬化、肥胖症、慢性阻塞性肺疾病和慢性疼痛等疾病的治疗。
• FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS
  申请人：Quibell Martin

  公开号：US20110009386A1

  公开（公告）日：2011-01-13

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R 3 and R 4 is H, and the other is selected from C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkoxy, and C 6-12 -aralkyl; or R 3 and R 4 are each independently selected from C 1-6 -alkyl and halo; R 9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.

  本发明的第一个方面涉及化合物式(I)的化合物，或其药学上可接受的盐、水合物、复合物或前药，其中：R3和R4中的一个是H，另一个选自C1-6烷基、C1-6卤代烷基、C1-6烷氧基和C6-12芳基烷基；或者R3和R4各自独立地选自C1-6烷基和卤素；R9是取代的5或6元杂环芳基或杂芳基基团或6,5-或6,6-螺合的双芳基或双杂芳基基团。式(I)的化合物表现出对人类卡特普辛S的惊人高效性，对其他哺乳动物卡特普辛具有良好的选择性，并可用于治疗风湿性关节炎、多发性硬化症、重症肌无力、移植排斥反应、糖尿病、Sjogren综合症、Grave病、系统性红斑狼疮、骨关节炎、牛皮癣、特发性血小板减少性紫癜、过敏性鼻炎、哮喘、动脉硬化、肥胖症、慢性阻塞性肺疾病和慢性疼痛等疾病的治疗。
• Liquid crystalline compound substituted with fluorine containing group, liquid crystal composition, and liquid crystal display device
  申请人：Chisso Corporation

  公开号：EP0761799A1

  公开（公告）日：1997-03-12

  Liquid crystalline compounds are disclosed which compounds are expressed by general formula (1) wherein R1 represents an alkyl group having 1 to 10 carbon atoms, ring A represents 1,4-phenylene or 1,4-cyclohexylene, each of X1, X2, X3, and X4 independently represents hydrogen atom or fluorine atom, Y1 represents CF3 or OCF3, and each of m, n, and p is independently an integer of 1 or 0. The liquid crystalline compounds have a wide temperature range of nematic phase, low viscosity, large positive Δε, high chemical stability, high miscibility with other liquid crystalline compounds at low temperatures, small temperature dependency of viscosity and Δε, extremely high specific resistance (high voltage holding ratio), and good UV stability, and are preferably used for TFT. Also, disclosed are liquid crystal compositions containing the liquid crystalline compounds mentioned above, and liquid crystal display devices using the liquid crystal composition.

  本发明公开了液晶化合物，该化合物由通式（1）表示 其中 R1 代表具有 1 至 10 个碳原子的烷基，环 A 代表 1,4-亚苯基或 1,4-环己烯，X1、X2、X3 和 X4 各自独立地代表氢原子或氟原子，Y1 代表 CF3 或 O ，m、n 和 p 各自独立地为 1 或 0 的整数。 这些液晶化合物具有向列相的温度范围宽、粘度低、正Δε大、化学稳定性高、在低温下与其他液晶化合物的混溶性高、粘度和Δε的温度依赖性小、极高的比电阻（高电压保持比）和良好的紫外线稳定性，最好用于 TFT。此外，还公开了含有上述液晶化合物的液晶组合物，以及使用该液晶组合物的液晶显示设备。